Fabtech Technologies Limited has informed the Exchange regarding Outcome of Board Meeting held on April 27, 2026.
FABTECH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts more than Nifty Microcap 250 and 4.4 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fabtech Technologies' board approved audited consolidated and standalone financial results for Q4 and FY ended March 31, 2026, with auditors Ajmera & Ajmera issuing an unmodified (clean) opinion. Consolidated FY26 revenue from operations rose ~25.8% YoY to ₹41,077.18 lakhs, but net profit fell ~17.4% to ₹3,835.80 lakhs because the prior year included a much larger exceptional gain (₹1,784.56 lakhs from an associate stake sale) versus only ₹177.49 lakhs this year (from selling a 51% stake in a subsidiary LLP). Q4 FY26 was strong, with consolidated net profit of ₹2,205.57 lakhs (up ~46% YoY). The board recommended a final dividend of ₹0.60 per share (₹10 face value), subject to shareholder approval. The company also authorized opening a new step-down subsidiary in Oman to expand its pharma turnkey projects business in the Middle East.
Positive on revenue momentum and the Oman expansion, but mixed on profitability – core operating margins compressed YoY. The dividend is modest (small payout per share) but signals confidence in cash generation post the October 2025 IPO, which strengthened the balance sheet with ~₹20,752 lakhs in fresh equity.